Oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) reflect pro-inflammatory properties of Lp(a) (lipoprotein(a)). The effect of OxPL-apoB on major adverse cardiovascular events (MACE) in ...

Pulmonary embolism (PE) continues to challenge clinicians with its complex presentation and potential for rapid deterioration. As the third leading cause of cardiovascular mortality in the U.S.

Randomized trials have shown that in patients with acute intermediate-high risk pulmonary embolism (PE), administration of systemic thrombolytics leads to less clinical deterioration, at the expense ...

Introduction PE is common and life-threatening. Thrombolysis with 100 mg alteplase is recommended in cardiac arrest and haemodynamic instability, 1 however best management for intermediate-risk PE is ...